Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7186571 | 0.93 | MASP2 (0.38) | TBXA2RLMNAALDH1A1MAPTDAGLA | |
| SCHEMBL7044843 | 0.91 | L3MBTL1 (0.39) | TBXA2RLMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7558531 | 0.89 | DAGLA (0.39) | TBXA2RLMNASMN1; SMN2DAGLACCR6 | |
| SCHEMBL7047180 | 0.83 | P2RX7 (0.37) | DAGLA | |
| SCHEMBL7049295 | 0.80 | DAGLA (0.41) | MAPTDAGLA | |
| SCHEMBL6467199 | 0.78 | DAGLA (0.41) | TBXA2RLMNASMN1; SMN2DAGLAHPGD | |
| SCHEMBL7567535 | 0.78 | DAGLA (0.43) | LMNADAGLA | |
| SCHEMBL7047182 | 0.77 | DAGLA (0.39) | ALDH1A1SMN1; SMN2DAGLAHSD17B10 | |
| SCHEMBL7049748 | 0.77 | XDH (0.40) | LMNAALDH1A1MAPTSMN1; SMN2DAGLA | |
| SCHEMBL7183270 | 0.77 | MGLL (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | TBXA2R 3395/4885LMNA 1755/4885ALDH1A1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.